New targetable oncogenes in non-small-cell lung cancer.
Boston, United States. In J Clin Oncol, 10 Apr 2013
A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements.
Structural Basis of RIP1 Inhibition by Necrostatins.
China. In Structure, 05 Apr 2013
Structural comparison of RIP1 with the inhibitor-bound oncogenic kinase B-RAF reveals partially overlapping binding sites for necrostatin and for the anticancer compound PLX4032.
To BRAF or not to BRAF: is that even a question anymore?
Lexington, United States. In J Neuropathol Exp Neurol, Jan 2013
Because the field has moved quickly during the past few years, there is not yet widespread awareness about what B-Raf normally does, how the BRAF gene is modified in gliomas, why mutant proteins promote gliomagenesis, and what an abnormal BRAF result means for diagnosis, prognosis, and treatment.
Adjuvant treatment of melanoma.
Sevilla, Spain. In Isrn Dermatol, Dec 2012
Several oncogenes have been identified in melanoma as BRAF, NRAS, c-Kit, and GNA11 GNAQ, each capable of activating MAPK pathway that increases cell proliferation and promotes angiogenesis, although NRAS and c-Kit also activate PI3 kinase pathway, including being more commonly BRAF activated oncogene.
[Predictive biomarkers for anti-EGFR antibodies].
Chiba, Japan. In Gan To Kagaku Ryoho, Nov 2012
Indeed, recent retrospective studies have shown that mutations in KRAS codon 61 and 146, BRAF, NRAS, and PIK3CA may also predict resistance to anti-EGFR antibodies in colorectal cancer patients.
Ioánnina, Greece. In Bull Acad Natl Med, Mar 2012
Key characteristics of the serrated neoplasia pathway include BRAF gene mutations, excess CpG island methylation, and subsequent microsatellite instability.